Adam Sonabend, MD, associate professor of Neurological Surgery, was senior author of the study published in Nature Communications. Northwestern Medicine scientists have developed a new non-invasive approach that could help better determine which patients with glioblastoma are responding favorably to chemotherapy treatment and inform future treatment plans, according to a recent study published in Nature Communications. Glioblastoma is the most common and aggressive primary brain tumor in adults, with a five-year survival rate of less than 7 percent, according to the National Brain Tumor Society. Determining whether a glioblastoma tumor is responding to therapy or continuing to grow may influence future management choices, such as the need for additional surgery, radiation or chemotherapy. The findings suggest the approach could be used as a real-time assessment for predicting chemotherapy response after blood-brain barrier opening in glioblastoma patients, which can help better inform a patient’s course of treatment and ultimately improve outcomes.